See the DrugPatentWatch profile for yervoy

At this point in time, there is no definitive answer as to when a generic version of Yervoy will become available. Yervoy, also known as ipilimumab, is a medication used to treat melanoma and is currently produced and marketed exclusively by Bristol Myers Squibb. The patent for Yervoy is set to expire in 2026 [1]. Once the patent expires, other companies will be able to produce and sell generic versions of the drug. However, it's important to note that it can take some time after a patent expires for generic versions of a drug to become available on the market.

It's worth noting that the process of bringing a generic drug to market can be complex and time-consuming. It involves several steps, including conducting clinical trials to demonstrate that the generic drug is equivalent to the brand-name drug in terms of safety and efficacy. This process can take several years to complete.

In summary, based on the available information, a generic version of Yervoy is not expected to be available until at least 2026. However, it's important to note that the exact timeline for the availability of a generic version of Yervoy is subject to change and will depend on a variety of factors, including the regulatory approval process.

Sources:
[1] <https://www.drugpatentwatch.com/drugs/yervoy>